United States Supreme Court
131 S.Ct. 2567 (2011)
Gladys Mensing and Julie Demahy (plaintiffs) filed separate suits in federal district courts against Pliva, Inc. (Pliva) and other manufacturers (defendants) of a generic drug for metoclopramide, claiming defendants failed to provide adequate warning labels for the drug. Metoclopramide was a drug designed to speed the movement of food through a person’s digestive system and to treat digestive tract problems such as diabetic gastroparesis and gastroesophageal reflux disorder. The Food and Drug Administration (FDA) first approved metoclopramide tablets under the brand name Reglan in 1980. Five years later, generic manufacturers, including defendants, began making the drug. Warning labels for the drug consistently changed over the years, the most recent of which warned individuals that tardive dyskinesia, a serious and often irreversible movement disorder, could develop in patients treated with metoclopramide. After taking the drug for several years, plaintiffs developed tardive dyskinesia. In both actions defendants maintained that federal law pre-empted the plaintiffs’ state tort claims. More specifically, defendants claimed that federal statutes and FDA regulations required it to use the same safety and efficacy labeling on the generic versions of the drug as their brand-name counterparts. The lawsuits were consolidated. The courts of appeal for the Fifth and Eighth Circuits concluded that plaintiffs’ claims were not pre-empted by federal law. Defendants appealed. The U.S. Supreme Court granted certiorari to review.
Rule of Law
Holding and Reasoning (Thomas, J.)
What to do next…
Unlock this case brief with a free (no-commitment) trial membership of Quimbee.
You’ll be in good company: Quimbee is one of the most widely used and trusted sites for law students, serving more than 97,000 law students since 2011. Some law schools—such as Yale, Vanderbilt, Berkeley, and the University of Illinois—even subscribe directly to Quimbee for all their law students. Read our student testimonials.
Learn more about Quimbee’s unique (and proven) approach to achieving great grades at law school.
Quimbee is a company hell-bent on one thing: helping you get an “A” in every course you take in law school, so you can graduate at the top of your class and get a high-paying law job. We’re not just a study aid for law students; we’re the study aid for law students. Read more about Quimbee.
Here's why 222,000 law students have relied on our case briefs:
- Written by law professors and practitioners, not other law students. 14,100 briefs, keyed to 189 casebooks. Top-notch customer support.
- The right amount of information, includes the facts, issues, rule of law, holding and reasoning, and any concurrences and dissents.
- Access in your classes, works on your mobile and tablet. Massive library of related video lessons and high quality multiple-choice questions.
- Easy to use, uniform format for every case brief. Written in plain English, not in legalese. Our briefs summarize and simplify; they don’t just repeat the court’s language.